Adherence

Adherence features

• 

  The generic generation

  In the next few years, some of the most widely used HIV drugs will come off patent in the UK. Gus Cairns asks: what are the...

  From:  HIV treatment update

• 

  Adherence and retention in HIV care in resource-limited settings

  Recent research on adherence to HIV treatment and retention in HIV care in resource-limited settings....

  From:  HIV & AIDS treatment in practice

• 

  Once-a-day pills and other sticky problems

  Less-than-perfect adherence to a once-a-day HIV treatment carries five times more risk of treatment failure than imperfect adherence to a twice-a-day regimen. That’s one of the surprising things...

  From:  HIV treatment update

• 

  In for the long haul

  With modern treatment, people with HIV can expect to live for decades and decades. But is this sustainable? How realistic is it to expect the drugs to...

  From:  HIV treatment update

• 

  Using mobile phones in HIV care and prevention

  This issues provides an over view of the growing role of mobile technology in HIV care and prevention in resource-poor settings. ...

  From:  HIV & AIDS treatment in practice

• 

  Adherence and long-term treatment success

  Taking your HIV medication correctly (the technical term for this is adherence) is the single most important thing you can do to make sure your HIV treatment...

  From:  HIV treatment update

• 

  How to deliver good adherence support: lessons from round the world

  A review of the barriers to good adherence to antiretroviral treatment in resource-limited settings, and the evidence of which interventions most successfully support adherence....

  From:  HIV & AIDS treatment in practice

• 

  A follow-up on follow-up: shifting to a community-based response to improve retention in care

  Further discussion on issues relating to retention in HIV care in low-income settings, with a focus on community-based care and task-shifting as potential solutions to...

  From:  HIV & AIDS treatment in practice

Adherence in your own words

• 

  Starting treatment wasn't as scary as I thought!

  I started learning about HIV treatment soon after I was first diagnosed. I had ‘the chat’ with someone, after I got my results – I...

  From: In your own words

• 

  Getting into the habit

  I try to take my HIV drugs at the same time every day, just before bed. I used to set an alarm on my mobile,...

  From: In your own words

• 

  Holiday hassles and HRT

  A much-needed holiday. Tickets, passports, driving licence – all go in my hand luggage. I leave the toiletry bag out till the last minute. I...

  From: In your own words

• 

  The Ikea approach

  I’ve no doubt that the main reason that I’m alive and well after 15 years of living with HIV is because combination therapy became available...

  From: In your own words

• 

  'I just take the tablets and get on with my life'

  I was diagnosed HIV-positive in 1997. I'm now 65. It was a bit of a shock. It could never happen to me, after all. I...

  From: In your own words

• 

  Jewelled friends

  I have a pretty little carved wooden pill box which I’d bought in Eureka, California. It holds my tablet set for the evening if I’m...

  From: In your own words

• 

  Time will tell

  I was devastated when I got the news that I was HIV-positive. But I was lucky to have such a supportive GP. It was thanks...

  From: In your own words

Adherence news from aidsmap

• One in five Americans living with HIV experience severe anxiety on an almost daily basis

  A fifth of HIV-positive adults in the United States regularly experience symptoms of anxiety, according to research published in AIDS. Individuals with symptoms of generalised anxiety disorder (GAD) had poor engagement with the HIV care continuum, and also had high ...

  04 July 2019 | Michael Carter

• Following an HIV treatment interruption, most children recover immunologically

  Just over one in ten (12%) children and adolescents living with HIV in Europe and Thailand take a break from antiretroviral treatment, usually as a result of their own decision, findings from the European Pregnancy and Paediatric HIV Cohort ...

  07 June 2019 | Carole Leach-Lemens

• High prevalence of stockouts of antiretroviral medicines in South Africa

  One in five public health facilities in South Africa were unable to supply at least one antiretroviral (ARV) or tuberculosis (TB) drug on the day they were contacted by researchers, while over a third had had a drug stockout in ...

  23 May 2019 | Alain Volny-Anne

• Most UK clinic staff now tell people about U=U, but not always in the same way

  Two presentations at this month’s British HIV Association (BHIVA) conference in Bournemouth show that most specialist healthcare workers are now informing people with HIV that if their viral load becomes undetectable as a result of taking antiretroviral therapy (ART), ...

  29 April 2019 | Gus Cairns

• Naltrexone implants provide better HIV treatment outcomes for those with HIV and opioid addiction in Russia

  A double-blind, placebo-controlled randomised trial conducted in Russia found that slow-release naltrexone implants resulted in better HIV treatment outcomes for people living with HIV and opioid dependence when compared to orally administered naltrexone. This research was carried out by Professor Evgeny ...

  19 April 2019 | Krishen Samuel

• Older black HIV-positive women have more mental distress than other women with HIV, but get less help for it

  A study looking at women aged over 45 living with HIV in the UK has found that while black African and Caribbean women experience greater social isolation and subjective mental distress than white women, they are less likely ...

  17 April 2019 | Gus Cairns

• Viral suppression maintained with alternate-day dosing of efavirenz/tenofovir/emtricitabine

  No significant differences in viral suppression between groups on daily dosing versus alternate-day dosing of combination fixed-dose tenofovir/emtricitabine/efavirenz (TDF/FTC/EFV, better known with the brand name of Atripla) were found in a randomised clinical trial published in AIDS by Dr Rita Bellagamba ...

  01 April 2019 | Krishen Samuel

• Non-adherence to HIV treatment for cost-saving reasons reported by 8% in American study

  Much of the excessive cost of prescription drugs in the United States falls on patients, and national surveillance data has now found that this has a real impact on HIV treatment outcomes. A study presented at the Conference on Retroviruses ...

  27 March 2019 | Roger Pebody

• Cocaine use associated with poor adherence to PrEP and dropping out of care

  Cocaine users have poorer adherence to HIV pre-exposure prophylaxis (PrEP) and engagement with care, according to research published in the online edition of the Journal of Acquired Immune Deficiency Syndromes. Even light cocaine use doubled the odds of having ...

  22 February 2019 | Michael Carter

• Reaching the men: who are the partners of the young women with HIV in South Africa?

  In the high-prevalence countries of southern Africa, young women under 25 bear the brunt of the epidemic, with continued high rates of HIV infection. So much so, that epidemiologists at the HIV Research for Prevention Conference ...

  05 November 2018 | Gus Cairns

More news

Adherence news selected from other sources

• Adults with HIV who have compassionate care providers start and remain in treatment longer

  Researchers find patients who perceive their primary care providers as lacking empathy and not willing to include them in decision making are at risk for abandoning treatment or not seeking treatment at all.

  15 July 2019 | ScienceDaily

• Researchers Discuss Ethics and Privacy Concerns About the Growing Field of HIV Adherence Monitoring

  We have several ways to measure adherence to treatment or pre-exposure prophylaxis (PrEP). But as technology changes, and the fields of HIV medicine and public health focus increasingly on monitoring viral suppression or drug concentrations in the body for PrEP, the questions about the ethics of certain technologies, their uses, and what happens to that data are still being debated.

  25 June 2019 | The Body Pro

• Many Women on HIV Treatment Are at Risk of Developing a Detectable Viral Load

  An ongoing study finds that considerable challenges in such women’s lives may compromise their adherence to antiretrovirals.

  22 May 2019 | Poz

• NIH Trial Evaluates Long-acting HIV Medication Unable to Adhere to Strict Daily Regimens

  A clinical trial to evaluate long-acting antiretroviral therapy (ART) for maintaining HIV suppression in people for whom adhering to conventional daily oral ART has been a challenge has begun at research sites across the United States. The study, called Long-Acting Therapy to Improve Treatment Success in Daily Life, or LATITUDE, will help determine whether a combination of two experimental injectable formulations of ART are superior to conventional oral ART in managing HIV infection in this population.

  09 May 2019 | National Institute of Allergy and Infectious Diseases

• 'Vast majority' of elevated viral load episodes in pregnant women caused by non-adherence

  Non-adherence to ART — and not pretreatment drug-resistant mutations — explain the “vast majority” of elevated viral load episodes in women initiating ART during pregnancy, according to results from a study conducted in South Africa.

  02 April 2019 | Healio

• Long-acting injectible antiretroviral trial begins

  Can a monthly injection of two antiretroviral drugs offer a better chance of suppressing the virus than current oral regimens, among individuals with adherence challenges? A trial that will enroll some 350 volunteers with documented lapses in treatment in the preceding year and a half will seek to find out, the National Institutes of Health announced today.

  28 February 2019 | Science Speaks

• Uganda: Financial incentives do not boost HIV viral suppression rate

  Financial incentives had no effect on viral suppression among HIV-positive adults in Uganda, according to a recent study. Researchers said these findings suggest a need for better interventions to promote the achievement of viral suppression.

  25 January 2019 | Healio

• Indonesia turns to Global Fund to ensure ARV stock

  Amid rising concerns about the availability of antiretroviral (ARV) therapy drugs following a failed drug tender, the government has given assurances that stocks are enough until the end of this year.

  23 January 2019 | The Jakarta Post

• What stops people with HIV adhering to long term antiretroviral therapy?

  Long term adherence to antiretroviral therapy (ART) is important in both reducing morbidly and mortality in people living with HIV and reducing transmission rates. A new study published in AIDS Research and Therapy explores people’s reasons for non-adherence to ART through a cohort in Uganda. They find travel, stigma, poor adherence education, and alternative medicine to be prominent factors.

  22 January 2019 | BMC Blogs Network

• Substance use does not lower adherence to PrEP in MSM

  Study findings showed that substance use does not affect adherence to HIV pre-exposure prophylaxis, or PrEP, among men who have sex with men or transgender women.

  24 November 2018 | Healio

More news